Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, February 24, 2026
Sygnature Discovery, a drug discovery contract research organization (CRO), announced a strategic brand relaunch, including a new website.
read more
Lantheus Holdings has entered into an agreement with NanoMab Technology, a biopharmaceutical company focusing on the development of next generation radiopharmaceuticals to be used in the development of immuno-oncology therapies.
read more
Thursday, September 12, 2024
Temperature-controlled container specialists Tower Cold Chain and CRYOPDP have partnered to enhance their product offerings to the pharmaceutical supply chain. The collaboration aims to provide an expanded range of solutions, specifically for ...
read more
Friday, February 26, 2016
Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, has been selected as the Contract Research Organization for Infinity Pharmaceuticals, Inc. ...
read more
Wednesday, August 30, 2023
Almac Diagnostic Services, a member of the Almac Group, has announced investment to expand its Next Generation Sequencing (NGS) capabilities for BioPharma partners, following the purchase and installation of the first Illumina NovaSeq™ X Plus ...
read more
Thursday, September 05, 2024
Emmes has been selected by the National Institutes of Health's (NIH) NIDA [National Institute of Drug Abuse] to support their Clinical Trials Network (CTN) for a multi-task, IDIQ contract.
read more
Wednesday, February 18, 2026
OFD Life Sciences, a division of Oregon Freeze Dry, announced that Danielle Grosso has joined the organization as the Senior Director of Project Management.
read more
Wednesday, October 19, 2022
Piramal Pharma Limited (PPL) announced that Yapan Bio has expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, India.
read more
LakePharma has announced the launch of GMP manufacturing of recombinant proteins and antibodies with CHO-GSN™ and TunaCHO™ platforms at its Hayward, California facility.
read more
The Almac Group Ltd, Is pleased to announce plans to make its ALM AADx assay – a gene expression test developed by its Diagnostics Business Unit – available for clinical use in 2015. Further validation of the test in ovarian cancer is on track for ...
read more
PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced the award of a US$3.3 million contract from the US Defense Threat Reduction Agency (DTRA) to develop biodefence vaccine adjuvants using the company’s ...
read more
PwC US announced that the firm has been awarded a government contract to aid in the mission of the US Agency for International Development (USAID) to support the advancement of global health.
read more
Wednesday, September 16, 2015
Medivir AB has announced that, as the next step in the company's optimization process, its research and development operations will be merged into a joint unit as of 1 October 2015, headed by Richard Bethell who will hold the new title of EVP ...
read more
Under a license agreement with the HMRI for development of clinical grade RNA manufacturing services, VGXI announced it has completed all of the partnership’s Phase I initiatives and anticipates Phase II will conclude by 4Q 2019.
read more
IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, announced that F-star Therapeutics dosed the first patients in a Phase 1 clinical trial, with FS222, a CD137/PD-L1 bispecific antibody.
read more